# US 2017/0281701 A1 · Formulation for the Nebulization of Oil Based Substances Suitable for Use with a Vibrating Mesh Nebulizer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281701 A1
- Document ID: US20170281701A1
- Status: Published application
- Kind: A1
- Application number: 15/479,251
- Filed: 2017-04-04
- Published: 2017-10-05
- Earliest claimed: 2016-04-05
- Inventors: Catherine Ket Wah Kan
- Web page: https://patentgrep.com/patent/US20170281701A1

## CPC

- A61K 36/3482: {Cannabis}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 15/00: Inhalators {(drug delivery in endotracheal tubes A61M16/04)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Several variations of formulations are used as a water base solution to disperse oil soluble pharmaceuticals, including cannabis extract, suitable for use with a VMN. Common elements include added small amount of sodium electrolytes to facilitate the nebulization process and ethanol in controlled amount as needed to dilute or dissolve thick waxy substances such as found in some cannabis extracts. Surfactants, co-surfactants and/or emulsifiers to include but not limited to Acconon™, ethanol, hydroxylated soy lecithin and/or sodium lauryl sulfate are used. The ingredients are sonicated to obtain a uniform respirable liposomal suspension that could be delivered in low micron range using a VMN for efficient absorption into the blood stream by oral inhalation.

## Claims

### Claim 1

Pharmaceutical formulations of a base solution, suitable for the delivery of various oil based substances, including various concentration and ratio of CBD to THC in a cannabis extract, using a VMN. The formulations comprise of a water base liquid, wherein the liquid is made up of a mixture of added cannabis oil extract having a predetermined amount of a medicinal cannabis compound; and an aerosol precursor with an emulsifier and/or surfactant with electrolytes forming liposomes by sonication.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the water base liquid can be delivered in an aerosol.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the water base liquid can be delivered in a liposomal micro-emulsified form.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the water base liquid is able to be nebulized effectively by a nebulizer including but not limited to a VMN that is capable of delivering respirable solution particles in a Mass Median Aerodynamic Diameter (MMAD) of 2-3 microns, thus enhancing the bioavailability of the medicinal compound for absorption.

### Claim 5 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the medicinal cannabis compound of known amount comprises none or one to more cannabinoid(s).

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the medicinal cannabis compound of known amount comprises none or one to more terpene(s).

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the medicinal cannabis compound of known amount comprises none or one to more flavonoid(s) and/or phytosterol(s).

### Claim 8 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the known amount of the medicinal cannabis compound is delivered in a single unit dose or in a titratable dose format.

### Claim 9 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the aerosol precursor comprises of various entities or a combination thereof of inhalable solvents, water base solutions, emulsifiers and/or surfactants along with cannabis in various concentration with or without added fat soluble supplements.

### Claim 10 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the water base liquid formulation nebulizes without any heat source.

### Claim 11 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the water base liquid formulation nebulizes without smoke or exhale.

### Claim 12 (depends on 1, 4)

The pharmaceutical formulation of claims 1 and 4, wherein the rate of nebulization could be pre-programed and the dose varied by the number of actuation of the VMN, the rate of nebulization and/or the length of time of nebulization per actuation of the device.

### Claim 13 (depends on 1)

The pharmaceutical formulation of claim 1, wherein any one or more cannabinoid(s) can be administered separately at separate times, simultaneously or sequentially to another one or more cannabinoid(s).

### Claim 14 (depends on 1, 5)

The pharmaceutical formulation of claims 1 and 5, wherein the cannabis extracts could be obtained by, but not limited to, supercritical CO2 extraction, decarboxylation, hydro pressure extraction, volatilization with a heated gas, synthetic and/or biosynthetic reengineering.

### Claim 15 (depends on 1)

The pharmaceutical formulation of claim 1 could be mixed using sonication, ultrasonic or micro fluidizer.

### Claim 16 (depends on 1)

The pharmaceutical formulation of claim 1 utilizes the addition of sodium salt as in sodium lauryl sulfate or sodium chloride to enhance the nebulization efficiency of the VMN for use with oil base pharmaceuticals such as cannabis extract or hemp oil or combination thereof.

### Claim 17 (depends on 1)

The pharmaceutical formulation of claim 1 can vary the percentage and type of lecithin with cannabis extracts in a preferred 1:1 ratio.

### Claim 18 (depends on 1)

The pharmaceutical formulation of claim 1 can vary the concentration or purity of the cannabis extract from 0 to 100% and proportionately lowering the alcohol content with increasing purity from 10 to 0%.

### Claim 19 (depends on 1)

The pharmaceutical formulation of claim 1 could use hemp oil to dilute concentrated cannabis extract and reduce the alcohol content from 10 to 0%.

### Claim 20 (depends on 1)

The pharmaceutical formulation of claim 1 could add 0.001 to 0.003% of benzalkonium chloride as a preservative if it is without alcohol and not in a unit dose format.
